Sakar Healthcare Ltd
NSE:SAKAR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sakar Healthcare Ltd
Depreciation & Amortization
Sakar Healthcare Ltd
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sakar Healthcare Ltd
NSE:SAKAR
|
Depreciation & Amortization
₹208.8m
|
CAGR 3-Years
29%
|
CAGR 5-Years
24%
|
CAGR 10-Years
24%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Depreciation & Amortization
₹19.1B
|
CAGR 3-Years
17%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Depreciation & Amortization
₹11.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
Depreciation & Amortization
₹4.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Lupin Ltd
NSE:LUPIN
|
Depreciation & Amortization
₹12.8B
|
CAGR 3-Years
11%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Depreciation & Amortization
₹8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
Sakar Healthcare Ltd
Glance View
Sakar Healthcare Ltd. engages in the manufacture of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2016-10-14. The firm is engaged in the manufacturing of pharmaceutical products providing liquid orals, cephalosporin tablets, capsules, dry powder syrup, dry powder injections, liquid injectable (SVP) in ampoules, vials & lyophilized injections, oral solid dosages, and research & development of the above products. The Company’s products include Oral - Liquid Syrup & Suspension, Liquid Injectable (SVP)-Vials & Ampoules, Cephalosporin - Dry Powder Injections, Cephalosporin Oral Solid and Lyophilised Injections (In Vials). The firm operates as a contract manufacturer for multinational pharmaceutical companies. The firm serves various countries such as Southeast Asia, Asia, Africa-Anglo & Francophone, MENA, America, covering approximately 38 countries. The Company’s subsidiaries include Sakar Oncology Private Limited.
See Also
What is Sakar Healthcare Ltd's Depreciation & Amortization?
Depreciation & Amortization
208.8m
INR
Based on the financial report for Mar 31, 2025, Sakar Healthcare Ltd's Depreciation & Amortization amounts to 208.8m INR.
What is Sakar Healthcare Ltd's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
24%
Over the last year, the Depreciation & Amortization growth was 16%. The average annual Depreciation & Amortization growth rates for Sakar Healthcare Ltd have been 29% over the past three years , 24% over the past five years , and 24% over the past ten years .
